Develops and commercializes therapies primarily for eye diseases, focusing on retinal conditions. Now — the numbers.
This is an established company with proven profits.
An average decline of 73% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
If every debt were paid off today, $20.8M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $20.8M in the vault; even if every debt were paid off, $20.8M would remain.
The stock sits at $0.01. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 4 years, sales fell about 73% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.